-$0.13 Earnings Per Share Expected for KITOV PHARMA LT/S (NASDAQ:KTOV) This Quarter

Share on StockTwits

Wall Street brokerages predict that KITOV PHARMA LT/S (NASDAQ:KTOV) will announce ($0.13) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for KITOV PHARMA LT/S’s earnings. The business is expected to announce its next quarterly earnings results on Monday, January 1st.

According to Zacks, analysts expect that KITOV PHARMA LT/S will report full year earnings of ($0.46) per share for the current year. For the next year, analysts expect that the firm will report earnings of ($0.23) per share. Zacks’ EPS averages are an average based on a survey of sell-side analysts that that provide coverage for KITOV PHARMA LT/S.

Separately, HC Wainwright reiterated a “buy” rating on shares of KITOV PHARMA LT/S in a report on Wednesday, October 16th.

Shares of NASDAQ:KTOV opened at $0.71 on Friday. The company has a market cap of $14.45 million, a P/E ratio of 1.82 and a beta of 3.55. The business has a fifty day simple moving average of $0.73 and a 200-day simple moving average of $0.82. KITOV PHARMA LT/S has a 52 week low of $0.56 and a 52 week high of $2.92.

A hedge fund recently raised its stake in KITOV PHARMA LT/S stock. Morgan Stanley grew its holdings in KITOV PHARMA LT/S (NASDAQ:KTOV) by 79.8% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 58,240 shares of the company’s stock after acquiring an additional 25,840 shares during the period. Morgan Stanley owned about 0.37% of KITOV PHARMA LT/S worth $55,000 as of its most recent SEC filing. 0.16% of the stock is owned by institutional investors and hedge funds.

About KITOV PHARMA LT/S

Kitov Pharma Ltd, through its subsidiaries, operates as a development stage biopharmaceutical company in Israel. It develops combination drugs for the simultaneous treatment of pain caused by osteoarthritis and hypertension. The company's lead drug candidate is KIT-302, a fixed dosage combination product based on the generic drugs celecoxib and amlodipine besylate that has completed its Phase III clinical study.

Featured Story: Back-End Load

Get a free copy of the Zacks research report on KITOV PHARMA LT/S (KTOV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for KITOV PHARMA LT/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KITOV PHARMA LT/S and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.